181 related articles for article (PubMed ID: 22185567)
21. Induced pluripotent stem cell-derived gamete-associated proteins incite rejection of induced pluripotent stem cells in syngeneic mice.
Kim EM; Manzar G; Zavazava N
Immunology; 2017 Jun; 151(2):191-197. PubMed ID: 28185259
[TBL] [Abstract][Full Text] [Related]
22. In vitro characterization of neurite extension using induced pluripotent stem cells derived from lissencephaly patients with TUBA1A missense mutations.
Bamba Y; Shofuda T; Kato M; Pooh RK; Tateishi Y; Takanashi J; Utsunomiya H; Sumida M; Kanematsu D; Suemizu H; Higuchi Y; Akamatsu W; Gallagher D; Miller FD; Yamasaki M; Kanemura Y; Okano H
Mol Brain; 2016 Jul; 9(1):70. PubMed ID: 27431206
[TBL] [Abstract][Full Text] [Related]
23. How far are induced pluripotent stem cells from the clinic?
Li M; Chen M; Han W; Fu X
Ageing Res Rev; 2010 Jul; 9(3):257-64. PubMed ID: 20362696
[TBL] [Abstract][Full Text] [Related]
24. Potent tumor tropism of induced pluripotent stem cells and induced pluripotent stem cell-derived neural stem cells in the mouse intracerebral glioma model.
Yamazoe T; Koizumi S; Yamasaki T; Amano S; Tokuyama T; Namba H
Int J Oncol; 2015 Jan; 46(1):147-52. PubMed ID: 25310640
[TBL] [Abstract][Full Text] [Related]
25. Evolution of induced pluripotent stem cell technology.
Zhou H; Ding S
Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
[TBL] [Abstract][Full Text] [Related]
26. Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells.
Lin YC; Ku CC; Wuputra K; Liu CJ; Wu DC; Satou M; Mitsui Y; Saito S; Yokoyama KK
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791215
[TBL] [Abstract][Full Text] [Related]
27. Brief Report: Immune Microenvironment Determines the Immunogenicity of Induced Pluripotent Stem Cell Derivatives.
Todorova D; Kim J; Hamzeinejad S; He J; Xu Y
Stem Cells; 2016 Feb; 34(2):510-5. PubMed ID: 26439188
[TBL] [Abstract][Full Text] [Related]
28. Use of constitutive and inducible oncogene-containing iPSCs as surrogates for transgenic mice to study breast oncogenesis.
Nguyen C; Nguyen JPT; Modi AP; Ahmad I; Petrova SC; Ferrell SD; Wilhelm SR; Ye Y; Schaue D; Barsky SH
Stem Cell Res Ther; 2021 May; 12(1):301. PubMed ID: 34044885
[TBL] [Abstract][Full Text] [Related]
29. Efficient, Selective Removal of Human Pluripotent Stem Cells via Ecto-Alkaline Phosphatase-Mediated Aggregation of Synthetic Peptides.
Kuang Y; Miki K; Parr CJC; Hayashi K; Takei I; Li J; Iwasaki M; Nakagawa M; Yoshida Y; Saito H
Cell Chem Biol; 2017 Jun; 24(6):685-694.e4. PubMed ID: 28529132
[TBL] [Abstract][Full Text] [Related]
30. Direct reprogrammed neuronal cells as a novel resource for cell transplantation therapy.
Yamashita T; Abe K
Cell Transplant; 2014; 23(4-5):435-9. PubMed ID: 24621988
[TBL] [Abstract][Full Text] [Related]
31. Induced pluripotent stem cells and their implication for regenerative medicine.
Csobonyeiova M; Polak S; Koller J; Danisovic L
Cell Tissue Bank; 2015 Jun; 16(2):171-80. PubMed ID: 25037593
[TBL] [Abstract][Full Text] [Related]
32. Disease characterization using LQTS-specific induced pluripotent stem cells.
Egashira T; Yuasa S; Suzuki T; Aizawa Y; Yamakawa H; Matsuhashi T; Ohno Y; Tohyama S; Okata S; Seki T; Kuroda Y; Yae K; Hashimoto H; Tanaka T; Hattori F; Sato T; Miyoshi S; Takatsuki S; Murata M; Kurokawa J; Furukawa T; Makita N; Aiba T; Shimizu W; Horie M; Kamiya K; Kodama I; Ogawa S; Fukuda K
Cardiovasc Res; 2012 Sep; 95(4):419-29. PubMed ID: 22739119
[TBL] [Abstract][Full Text] [Related]
33. Elimination of Teratogenic Human Induced Pluripotent Stem Cells by Bee Venom via Calcium-Calpain Pathway.
Kim A; Lee SY; Kim BY; Chung SK
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380745
[TBL] [Abstract][Full Text] [Related]
34. Single-cell sequencing reveals the potential oncogenic expression atlas of human iPSC-derived cardiomyocytes.
Ou M; Zhao M; Li C; Tang D; Xu Y; Dai W; Sui W; Zhang Y; Xiang Z; Mo C; Lin H; Dai Y
Biol Open; 2021 Feb; 10(2):. PubMed ID: 33589441
[TBL] [Abstract][Full Text] [Related]
35. Inducing iPSCs to escape the dish.
Barrilleaux B; Knoepfler PS
Cell Stem Cell; 2011 Aug; 9(2):103-11. PubMed ID: 21816362
[TBL] [Abstract][Full Text] [Related]
36. Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs): A new approach to finding targets for cervical cancer stem cell treatment.
Sato M; Kawana K; Adachi K; Fujimoto A; Yoshida M; Nakamura H; Nishida H; Inoue T; Taguchi A; Ogishima J; Eguchi S; Yamashita A; Tomio K; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40935-40945. PubMed ID: 28402962
[TBL] [Abstract][Full Text] [Related]
37. A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy.
Ando M; Nishimura T; Yamazaki S; Yamaguchi T; Kawana-Tachikawa A; Hayama T; Nakauchi Y; Ando J; Ota Y; Takahashi S; Nishimura K; Ohtaka M; Nakanishi M; Miles JJ; Burrows SR; Brenner MK; Nakauchi H
Stem Cell Reports; 2015 Oct; 5(4):597-608. PubMed ID: 26321144
[TBL] [Abstract][Full Text] [Related]
38. Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine.
Qiao Y; Agboola OS; Hu X; Wu Y; Lei L
Stem Cell Rev Rep; 2020 Dec; 16(6):1049-1061. PubMed ID: 32939647
[TBL] [Abstract][Full Text] [Related]
39. Direct
Xiang M; Lu M; Quan J; Xu M; Meng D; Cui A; Li N; Liu Y; Lu P; Kang X; Wang X; Sun N; Zhao M; Liang Q; Le L; Wang X; Zhang J; Chen S
Theranostics; 2019; 9(1):290-310. PubMed ID: 30662568
[TBL] [Abstract][Full Text] [Related]
40. Application of Cancer Cell Reprogramming Technology to Human Cancer Research.
Pan XY; Tsai MH; Wuputra K; Ku CC; Lin WH; Lin YC; Kishikawa S; Noguchi M; Saito S; Lin CS; Yokoyama KK
Anticancer Res; 2017 Jul; 37(7):3367-3377. PubMed ID: 28668824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
